– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p
NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
Watch NewAmsterdam Pharma's latest callNewamsterdam Pharma (NASDAQ:NAMS) Q2 2026 Earnings Call · Replay · Aug 5Read the transcript of Newamsterdam Pharma (NASDAQ:NAMS) Q2 2026 Earnings CallNewAmsterdam Pharma Company N.V. on 6ix
In the deck
Story so far
- NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023
- NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
- NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
Earlier from NewAmsterdam Pharma
- NewAmsterdam Pharma to Present at Jefferies Healthcare Conference
- NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023
- NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights
- NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
- NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
Later from NewAmsterdam Pharma
- NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients
- NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares
- NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares
- NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares
- NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease
Follow NewAmsterdam Pharma into a list and get an email when it puts out news.
Follow NewAmsterdam Pharma